First-in-Human (FIH)
First-in-Human (FIH) studies represent a critical milestone in the development of new therapies. CenExel provides the scientific expertise, operational excellence, and specialized infrastructure required to safely transition investigational treatments from preclinical research into human clinical trials. Our experienced teams support sponsors through every stage of early-phase development, delivering high-quality data and efficient study execution.
Studies Conducted
0
+
Trial Participants
0
+
Active Centers
0
Overview
Leading First-in-Human Clinical Research
CenExel's First-in-Human research programs are designed to help sponsors evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of investigational therapies in humans for the first time. Our experienced investigators and research teams provide comprehensive support for early-phase clinical development across a wide range of therapeutic areas.
From protocol development and site activation to patient monitoring and data collection, we deliver reliable execution and scientific rigor that help sponsors make informed development decisions with confidence.
Conditions Covered
First-in-Human Conditions We Research
Our acute First-in-Human research sites support a broad spectrum of post-operative and procedure-related pain conditions.
Central Nervous System (CNS)
Psychiatry & Behavioral Health
Pain & Inflammation
Metabolic Disorders
Rare Diseases
Immunology
Gastroenterology
Neurology
Cardiovascular Diseases
Respiratory Disorders
Our Approach
Why Sponsors Choose CenExEl for First-in-Human Studies
Our First-in-Human expertise extends beyond participant enrollment—we provide strategic scientific guidance, operational excellence, and high-quality data to support confident early-phase decision-making.
01
Early-Phase Expertise
Experienced investigators and scientific leaders support safe and efficient first-in-human study execution.
02
Advanced Clinical Pharmacology Capabilities
Comprehensive PK/PD assessments, biomarker analysis, and dose-escalation expertise.
03
Intensive Safety Monitoring
Dedicated medical oversight and real-time safety evaluations throughout study participation.
04
Rapid Study Start-Up
Streamlined site activation, participant recruitment, and operational processes designed to accelerate timelines.
Phase Coverage
Supported Trial Phases
We support early clinical development programs for First-in-Human studies, providing scientific expertise and operational excellence.
Active Phases
Phase I
Phase II
Our Phase I capabilities include single ascending dose (SAD), multiple ascending dose (MAD), food effect studies, drug-drug interaction studies, bioavailability assessments, biomarker-driven research, and proof-of-concept trials.
Let’s Advance Your Next Study
Looking for an experienced clinical research partner with the expertise, capabilities, and reach to move your study forward? Connect with CenExel to discuss your needs and explore how our network can support your clinical development goals.
Explore Our Network
Discover CenExel’s Centers of Excellence and find the locations, therapeutic expertise, and capabilities that align with your clinical development needs.